Tonic-Clonic Seizures Treatment Market Report and Forecast 2024-2032

Tonic-Clonic Seizures Treatment Market Size

The tonic-clonic seizures treatment market is expected to grow at a CAGR of 6% during the forecast period of 2024-2032, driven by the increased research activities and clinical trials aimed at finding new treatments and the rising introduction of generic treatment options for tonic-clonic seizures.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Tonic-Clonic Seizures Treatment Market Outlook

• The increasing prevalence of epilepsy and related seizure disorders is a major driver of the market.

• Growth in research activities and clinical trials aimed at finding new treatments for tonic-clonic seizures are poised to elevate the market value in the forecast period.

• The increased availability of generic drugs, rising demand for combination therapies, and growing awareness about tonic-clonic seizures are some of the factors impacting market dynamics.

Tonic-Clonic Seizures Treatment Market Overview

Tonic-clonic seizures, also called grand mal seizures, refer to a type of generalized seizure that affects the entire brain of the individual. Tonic-clonic seizures combine the characteristics of tonic and clonic seizures, as the name implies. Tonic refers to stiffening, while clonic refers to rhythmical jerking. For the diagnosis of the tonic-clonic, the medical history is reviewed prior to the tests such as neurological exams, blood tests, electroencephalogram (EEG), computerized tomography (CT) scan, and others. The continued cooperation of many organizations and governments in the fight against the stigma associated with epilepsy and seizures has resulted in increased awareness and a corresponding increase in demand for treatment.

Increased clinical trial activity has resulted in a stronger product pipeline, which is contributing to market growth. Technological advancements and increased investments in R&D activities have paved the way for a variety of novel treatment options. Furthermore, increased healthcare budget and spending and improved healthcare infrastructure are expected to support market growth over the forecast period.

Tonic-Clonic Seizures Treatment Market Growth Drivers

Increasing Availability of Generic Medications for Tonic-Clonic Seizures to Support Market Growth

The market is witnessing an increased availability of generic drugs, which are generally less expensive than the branded versions. For instance, in July 2024 , the global pharmaceutical company, Lupin, announced that it had received approval for its Abbreviated New Drug Application (ANDA) for Topiramate Extended-Release Capsules from the United States Food and Drug Administration (U.S. FDA). The company will manufacture and market Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, and 200 mg, which is a generic version of Trokendi XR Extended-Release Capsules, 25 mg, 50 mg, 100 mg, and 200 mg, developed by Supernus Pharmaceuticals. This generic medication is indicated for partial-onset or primary generalized tonic-clonic seizures in patients (aged 6 years of age or above) and will be produced at Lupin’s Pithampur facility in India.

Thus, the increasing introduction of generic options is expected to improve treatment accessibility and also drive market growth.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Tonic-Clonic Seizures Treatment Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Increasing Research and Clinical Trials to Affect the Market Landscape 

The market is witnessing an increase in research activities and clinical trials aimed at finding new treatments and improving existing therapies for tonic-clonic seizures. These research initiatives are supported by increased investment from research institutions and pharmaceutical companies in order to develop innovative treatments and evaluate their effectiveness through clinical trials. This rising focus on research for tonic-clonic seizures is expected to fuel market growth.

Growing Focus on Combination Therapies to Augment Tonic-Clonic Seizures Treatment Market Demand

The increased focus on combination therapies is a significant trend that is likely to bolster the market demand. Combination therapies are increasingly adopted by patients who do not respond well to monotherapy. This treatment strategy targets multiple pathways involved in seizure generation, which often results in better clinical outcomes. In addition, combination therapy is widely prescribed for patients who develop resistance to a single anti-epileptic drug.

Rising Awareness Campaigns to Elevate the Tonic-Clonic Seizures Treatment Market Value

In June 2024 , a charitable organization in England and Wales, Epilepsy Action (British Epilepsy Association), launched its first TV ad campaign featuring a first-aid video on how to help someone who is having a tonic-clonic seizure. This initiative was directed at raising awareness about epilepsy and tonic-clonic seizure aid. Such awareness initiatives and educational programs are expected to contribute to earlier diagnosis and treatment, which is likely to elevate the market value in the coming years.

Adoption of Advanced Anti-Seizure Medications to Influence Tonic-Clonic Seizures Treatment Market Dynamics

One of the major trends in the market is the growing adoption of novel anti-seizure medications that are linked with improved efficacy and safety profiles compared to traditional treatment options. The popularity of medications such as levetiracetam, lamotrigine, and lacosamide is rising in the market due to their better tolerability and fewer side effects. In addition, the development of anti-seizure drugs that target specific seizure mechanisms is projected to aid market expansion.

Tonic-Clonic Seizures Treatment Market Segmentation

Market Breakup by Drug Class
     

• Barbiturates

• Hydantoin

• Phenyltriazine

• Iminostilbenes

• Others

Market Breakup by Drug Generation
     

• First

• Second

• Third

Market Breakup by Route of Administration

• Oral

• Parenteral

• Others

Market Breakup by End User
 

• Hospital and Clinics

• Ambulatory Surgical Centers

• Others

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
• Japan

• India

Tonic-Clonic Seizures Treatment Market Share

Drug Class Segment Represents a Major Market Share

The market is segmented by drug class into barbiturates, hydantoin, phenyltriazine, iminostilbenes, and others. The market value of this segment is influenced by the introduction of new drugs and changes in treatment guidelines. The hydantoin segment is experiencing significant demand in the market and is commonly prescribed as a first-line treatment for tonic-clonic seizures. The efficacy of hydantoins such as the phenytoin drug in controlling seizures and the established safety drives their popularity in the market.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Tonic-Clonic Seizures Treatment Market Analysis by Region

In the United States, the market is driven by the increasing prevalence of epilepsy and the availability of advanced treatment options. The strong presence of pharmaceutical companies and a well-established healthcare infrastructure also support market expansion. The market also benefits from the rising adoption of newer antiepileptic drugs and growing awareness about seizure treatment. Further, increased focus on the development of novel therapeutics for tonic-clonic seizures is expected to fuel the growth in this regional market.

Leading Players in the Tonic-Clonic Seizures Treatment Market

The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:

GSK Group

Global healthcare company GSK (GlaxoSmithKline plc) has a significant presence in the market and offers medications indicated for epilepsy, including drugs targeting tonic-clonic seizures. One of their key drugs is Lamotrigine (Lamictal)  which helps to treat tonic-clonic seizures.

Eisai Co. Ltd.

Headquartered in Tokyo, Japan, this Japanese pharmaceutical company has a strong portfolio in the neurology market including tonic-clonic seizure treatment. Its anti-epileptic drug (AED) Fycompa®  is used for the treatment of partial-onset seizures and primary generalized tonic-clonic seizures.

Catalyst Pharmaceutical Co. Ltd.

Biopharmaceutical company Catalyst Pharmaceutical Co. Ltd. is based in Coral Gables, Florida. The company specializes in the development and commercialization of innovative therapies for rare neurological diseases, including epilepsy and other seizure disorders.

Otsuka Pharmaceutical Co. Ltd.

Japanese pharmaceutical company Otsuka Pharmaceutical Co. Ltd. is one of the leading players in the market and enjoys a strong presence in the neurology sector. Its anti-epileptic medication E Keppra® (generic name: levetiracetam)  is widely used for treating tonic-clonic and other types of seizures.

Other key players in the market include Prasco LLC, UCB Japan Co. Ltd., Pfizer Inc., Azurity Pharmaceuticals Inc., and GL Pharma.

Key Highlights of the Report

Key Questions Answered in the Tonic-Clonic Seizures Treatment Market Report

• What was the tonic-clonic seizures treatment market value in 2023?
• What is the tonic-clonic seizures treatment market forecast outlook for 2024-2032?
• What are the regional markets covered in the EMR report?
• What is market segmentation based on drug class?
• What is the market breakup based on drug generation?
• What is the market breakup by route of administration?
• Who are the major end users in the market?
• What are the major factors aiding the tonic-clonic seizures treatment market demand? 
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints? 
• Which regional market is expected to lead the market share in the forecast period? 
• Which country is expected to experience expedited growth during the forecast period? 
• How does the increasing prevalence of epilepsy and other seizure disorders affect the market landscape?
• What are the major tonic-clonic seizures treatment market trends?
• How does the growth in clinical trials impact the market size?
• Which drug class will dominate the market share? 
• Which drug generation is expected to have a high market value in the coming years?
• Which route of administration will experience the highest demand in the market segment?
• Which end user is projected to contribute to the highest market growth?
• Who are the key players involved in the tonic-clonic seizures treatment market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?

Tonic-Clonic Seizures Treatment Market Report Snapshots

Tonic-Clonic Seizures Treatment Market Size

Tonic-Clonic Seizures Treatment Companies